• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period.

作者信息

Boekel Laura, Besten Yaëlle R, Hooijberg Femke, Wartena Rosa, Steenhuis Maurice, Vogelzang Erik, Leeuw Maureen, Atiqi Sadaf, Tas Sander W, Lems Willem F, van Ham S Marieke, Eftimov Filip, Stalman Eileen W, Wieske Luuk, Kuijpers Taco W, Voskuyl Alexandre E, van Vollenhoven Ronald F, Gerritsen Martijn, Krieckaert Charlotte, Rispens Theo, Boers Maarten, Nurmohamed Mike T, Wolbink Gertjan

机构信息

Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, 1056 AB, Amsterdam, Netherlands.

Department of immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, Netherlands.

出版信息

Lancet Rheumatol. 2022 Nov;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1. Epub 2022 Aug 23.

DOI:10.1016/S2665-9913(22)00221-1
PMID:36034738
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9398211/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b414/9398211/ab08e2fe386f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b414/9398211/ab08e2fe386f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b414/9398211/ab08e2fe386f/gr1_lrg.jpg

相似文献

1
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period.在奥密克戎毒株占主导期间免疫介导性炎症疾病患者中的新型冠状病毒2型突破性感染
Lancet Rheumatol. 2022 Nov;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1. Epub 2022 Aug 23.
2
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.免疫介导的炎症性疾病患者中感染 SARS-CoV-2 奥密克戎（B.1.1.529）变异株的突破性感染。
Ann Rheum Dis. 2022 Dec;81(12):1757-1766. doi: 10.1136/ard-2022-222904. Epub 2022 Sep 5.
3
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.使用免疫抑制剂的免疫介导炎症性疾病的接种疫苗患者中出现的德尔塔（B.1.617.2）变异株导致的严重急性呼吸综合征冠状病毒2突破性感染：两项前瞻性队列研究的子研究
Lancet Rheumatol. 2022 Jun;4(6):e417-e429. doi: 10.1016/S2665-9913(22)00102-3. Epub 2022 Apr 29.
4
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.Omicron BA.1 变异株突破感染同源第三剂 Comirnaty® COVID-19 疫苗后的养老院居民：寻找保护相关因素。
J Med Virol. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. Epub 2022 May 25.
5
Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type.按病毒变种和疫苗类型调查新冠病毒突破性感染情况。
Front Microbiol. 2022 Nov 24;13:1027271. doi: 10.3389/fmicb.2022.1027271. eCollection 2022.
6
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
7
Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.完全接种疫苗的德尔塔或奥密克戎变异突破感染个体中的 SARS-CoV-2 抗体水平。
Nat Commun. 2022 Aug 1;13(1):4466. doi: 10.1038/s41467-022-32254-8.
8
Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.基于mRNA的第三剂和第四剂加强疫苗接种对慢性血液透析患者中SARS-CoV-2中和抗体滴度形成、无应答危险因素及SARS-CoV-2奥密克戎突破性感染后结局的影响：一项前瞻性多中心队列研究
J Clin Med. 2022 Jun 2;11(11):3187. doi: 10.3390/jcm11113187.
9
Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.评估中国广东省肇庆市未接种疫苗的个体和奥密克戎 BA.2 感染疫苗接种者针对 SARS-CoV-2 的抗体反应。
Virol J. 2022 Nov 25;19(1):197. doi: 10.1186/s12985-022-01912-0.
10
Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report.一名患有桥本甲状腺炎、恶性贫血和慢性萎缩性自身免疫性胃炎的自身免疫患者对SARS-CoV-2疫苗及后续突破性奥密克戎感染的免疫反应：病例报告
Vaccines (Basel). 2022 Mar 15;10(3):450. doi: 10.3390/vaccines10030450.

引用本文的文献

1
Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt.风湿性和肌肉骨骼疾病患者接种新冠病毒疫苗的安全性：埃及的一项横断面研究
Oman Med J. 2024 Sep 30;39(5):e676. doi: 10.5001/omj.2024.107. eCollection 2024 Sep.
2
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.肿瘤坏死因子抑制剂治疗的免疫介导炎症性疾病患者对第五剂二价SARS-CoV-2疫苗的体液和细胞反应：一项前瞻性队列研究
Lancet Reg Health Eur. 2024 Nov 15;48:101121. doi: 10.1016/j.lanepe.2024.101121. eCollection 2025 Jan.
3

本文引用的文献

1
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.使用免疫抑制剂的免疫介导炎症性疾病的接种疫苗患者中出现的德尔塔（B.1.617.2）变异株导致的严重急性呼吸综合征冠状病毒2突破性感染：两项前瞻性队列研究的子研究
Lancet Rheumatol. 2022 Jun;4(6):e417-e429. doi: 10.1016/S2665-9913(22)00102-3. Epub 2022 Apr 29.
2
SARS-CoV-2 Omicron variant: recent progress and future perspectives.SARS-CoV-2 奥密克戎变异株：最新进展与未来展望。
Signal Transduct Target Ther. 2022 Apr 28;7(1):141. doi: 10.1038/s41392-022-00997-x.
3
Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.
从患者角度出发探讨家庭指端采血检测对补充和促进风湿病学大型研究的可行性。
RMD Open. 2024 Apr 19;10(2):e003933. doi: 10.1136/rmdopen-2023-003933.
4
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.免疫抑制治疗患者中疫苗和混合免疫后 COVID-19 的发生率和结局：前瞻性队列研究中识别免疫后抗 RBD 抗体的保护性水平。
RMD Open. 2024 Apr 9;10(2):e003545. doi: 10.1136/rmdopen-2023-003545.
5
Work participation and the COVID-19 pandemic: an observational study in people with inflammatory rheumatic diseases and population controls.工作参与度与新冠疫情：一项针对炎症性风湿疾病患者及人群对照的观察性研究
Rheumatol Adv Pract. 2024 Mar 9;8(2):rkae026. doi: 10.1093/rap/rkae026. eCollection 2024.
6
Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases.系统性自身免疫性风湿病患者接受替沙格韦单抗/西加韦单抗治疗后的突破性 COVID-19 。
J Rheumatol. 2024 Mar 1;51(3):305-312. doi: 10.3899/jrheum.2023-0742.
7
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.奥密克戎变异株的流行和抗 SARS-CoV-2 疫苗接种是系统性自身免疫性风湿病患者 COVID-19 轻症化的关键决定因素。
Clin Rheumatol. 2023 Dec;42(12):3375-3385. doi: 10.1007/s10067-023-06769-4. Epub 2023 Sep 21.
8
Omicron variant infection in inflammatory rheumatological conditions - outcomes from a COVID-19 naive population in Aotearoa New Zealand.奥密克戎变异株在炎症性风湿性疾病中的感染——来自新西兰奥特亚罗瓦未感染过新冠病毒人群的结果
Lancet Reg Health West Pac. 2023 Jul 18;38:100843. doi: 10.1016/j.lanwpc.2023.100843. eCollection 2023 Sep.
9
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands.炎症性风湿疾病患者的新冠后状况：荷兰的一项前瞻性队列研究
Lancet Rheumatol. 2023 Jul;5(7):e375-e385. doi: 10.1016/S2665-9913(23)00127-3. Epub 2023 May 31.
10
Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages.奥密克戎各分支（包括 XBB 和 BQ.1 谱系）的所有编码和非编码区域的共识插入/缺失和氨基酸变异。
Arch Virol. 2023 May 8;168(6):156. doi: 10.1007/s00705-023-05787-6.
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis.
2021年3月1日至11月22日在加拿大安大略省对患有免疫介导的炎症性疾病的个体进行的SARS-CoV-2感染疫苗有效性及严重后果的基于人群的分析。
Lancet Rheumatol. 2022 Jun;4(6):e430-e440. doi: 10.1016/S2665-9913(22)00096-0. Epub 2022 Apr 14.
4
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.由于奥密克戎毒株，血液系统癌症和实体癌患者中出现了更多的新冠病毒突破性感染病例。
Cancer Cell. 2022 May 9;40(5):444-446. doi: 10.1016/j.ccell.2022.04.003. Epub 2022 Apr 12.
5
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.接种疫苗的风湿病患者中出现的SARS-CoV-2突破性感染：来自COVID-19全球风湿病联盟提供者登记处的结果。
RMD Open. 2022 Apr;8(1). doi: 10.1136/rmdopen-2021-002187.
6
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.风湿免疫性炎症性疾病未免疫患者 COVID-19 的抗体产生和疾病严重程度：来自前瞻性队列研究的数据。
RMD Open. 2022 Apr;8(1). doi: 10.1136/rmdopen-2021-002035.
7
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.免疫抑制剂治疗的免疫介导性炎症疾病患者接种第二剂和第三剂严重急性呼吸综合征冠状病毒2疫苗后的体液反应：一项队列研究
Lancet Rheumatol. 2022 May;4(5):e338-e350. doi: 10.1016/S2665-9913(22)00034-0. Epub 2022 Mar 17.
8
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎（B.1.1.529）和德尔塔（B.1.617.2）变异株的关系：一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
9
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.荷兰自身免疫性疾病患者接种新冠疫苗后的抗体产生情况：两项前瞻性队列研究数据的子研究
Lancet Rheumatol. 2021 Nov;3(11):e778-e788. doi: 10.1016/S2665-9913(21)00222-8. Epub 2021 Aug 6.
10
Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population.患有风湿性疾病的患者比普通人群更严格地遵守新冠疫情隔离措施。
Lancet Rheumatol. 2020 Oct;2(10):e583-e585. doi: 10.1016/S2665-9913(20)30286-1. Epub 2020 Aug 27.